<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7263255\results\search\country\results.xml">
  <result pre="(SARS) caused by SARS-CoV (Î²-CoV) emerged in Guangdong province of" exact="China" post="in 2002â€&quot;2003, and Middle East respiratory syndrome (MERS) caused"/>
  <result pre="East respiratory syndrome (MERS) caused by MERS-CoV (Î²-CoV) emerged in" exact="Saudi Arabia" post="in 2012. Both these CoVs were of bat origin"/>
  <result pre="selling dead seafood animals and trading of live animals. As" exact="China" post="had a quick surveillance system after the SARS outbreak,"/>
  <result pre="be an epidemic, initially spreading to other countries like Thailand," exact="South Korea," post="and Japan as there was massive Chinese migration due"/>
  <result pre="initially spreading to other countries like Thailand, South Korea, and" exact="Japan" post="as there was massive Chinese migration due to Chinese"/>
  <result pre="countries evacuated their respective citizens from Wuhan and travelers from" exact="China" post="and other affected countries were kept under quarantine/isolation for"/>
  <result pre="reduced in China, with a drastic increase in countries like" exact="the USA" post="with 6.44 lacs cases, Spain and Italy with almost"/>
  <result pre="increase in countries like the USA with 6.44 lacs cases," exact="Spain" post="and Italy with almost 1.8 and 1.6 lacs cases"/>
  <result pre="countries like the USA with 6.44 lacs cases, Spain and" exact="Italy" post="with almost 1.8 and 1.6 lacs cases each. Most"/>
  <result pre="form of viral pneumonia called COVID-19 that originated in Wuhan," exact="China" post="and was avowed a pandemic by WHO on 11th"/>
  <result pre="Phylogenetic origin Source/intermediate source Receptor Mortality rate Ro SARS-CoV-2 Wuhan," exact="China" post="Class I, Cluster IIa Bats/unknown ACE-2 2.3% 2â€&quot;2.5 SARS-CoV"/>
  <result pre="Bats/ palm civets or dromedary camels ACE-2 9.5% 1.7â€&quot;1.9 MERS-CoV" exact="Saudi Arabia" post="Class II Bats/ palm civets or dromedary camels DDP4"/>
  <result pre="ChiCTR2000029898, ChiCTR2000029899, ChiCTR2000029935 and ChiCTR2000029939) were immediately carried out in" exact="China" post="for the safety and efficacy of CQ and hydroxychloroquine"/>
  <result pre="repurposing of antiretroviral drug which have been previously approved by" exact="United States" post="Food and Drug Administration (FDA) is really helpful in"/>
  <result pre="(ARB) or Umifenovir is an antiviral drug currently approved in" exact="China" post="and Russia for the prophylaxis treatment of respiratory viral"/>
  <result pre="Umifenovir is an antiviral drug currently approved in China and" exact="Russia" post="for the prophylaxis treatment of respiratory viral infections and"/>
  <result pre="therapy alone or in combination therapy to treat COVID-19. Currently," exact="China" post="is conducting various studies to evaluate the potential of"/>
  <result pre="of ARB as a treatment option. A study conducted in" exact="China" post="reveals that ARB effectively inhibits SARS-CoV-2 infection at low"/>
  <result pre="Î¼M in vitro. The National Health Commission (NHC) of the" exact="People's Republic of China" post="has included ARB in the latest version of the"/>
  <result pre="in vitro. The National Health Commission (NHC) of the People's" exact="Republic of" post="China has included ARB in the latest version of"/>
  <result pre="The National Health Commission (NHC) of the People's Republic of" exact="China" post="has included ARB in the latest version of the"/>
  <result pre="open study has been initiated by Jieming QU, Rujin Hospital," exact="China" post="to observe the safety and efficacy of ARB in"/>
  <result pre="its action against RNA viruses. It was however approved in" exact="Japan" post="and France and not in other countries for a"/>
  <result pre="against RNA viruses. It was however approved in Japan and" exact="France" post="and not in other countries for a few indications"/>
  <result pre="(DRV) is a second-generation protease inhibitor against HIV-1. Scientists in" exact="China" post="declared on 4 February 2020 that DRV prevented in"/>
  <result pre="Oseltamivir with or without antibiotics and corticosteroids is reported in" exact="China" post="[116]. Oseltamivir is also used in clinical trials with"/>
  <result pre="are the possible adverse effects of tetracyclines. Nantes University Hospital," exact="France" post="has been given approval to start a double blinded,"/>
  <result pre="as weak [177]. Indeed, a study was performed in Wuhan" exact="China" post="identifying clinical outcomes of patients infected with COVID-19 (NÂ"/>
  <result pre="effective therapeutic alternative for severe COVID-19 infections. A group from" exact="China" post="administered a single 200Â ml dose of CP to"/>
  <result pre="inactivated virus vaccines and live attenuated vaccines (Serum Institute of" exact="India" post="with Codagenix). Johnson &amp;amp; Johnson is working on an"/>
  <result pre="Israel, Wroclaw Medical University, Poland, Oxford University Clinical Research Unit," exact="Vietnam" post="NCT04333628, NCT04331600, NCT04328493 2 Hydroxychloroquine 3, 3, 2, 2,"/>
  <result pre="COVID-19 disease Dr. Michael Hill, University of Calgary, Canada, Germany," exact="United States," post="Baylor University Medical Center, United States, California, Rambam Health"/>
  <result pre="of Calgary, Canada, Germany, United States, Baylor University Medical Center," exact="United States," post="California, Rambam Health Care Campus NCT04329611, NCT04340544, NCT04329923, NCT04333225,"/>
  <result pre="route Anti-Malarial/Anti-Infective Combination to treat COVID-19 patients HonorHealth Research Institute," exact="United States" post="NCT04339426 6 Lopinavir/ritonavir 2 Oral route Antiretroviral, to treat"/>
  <result pre="route Antiretroviral, to treat COVID-19 patients Sunnybrook Health Sciences Centre," exact="Canada" post="NCT04330690 7 Lopinavir/ritonavir vs Hydroxychloroquine sulfate 2 Oral route"/>
  <result pre="S.C injection To treat moderate to severe COVID-19 Lisa Barrett," exact="Canada" post="NCT04321993 9 Remdesivir, Lopinavir/ritonavir, interferon Î²-1A, and hydroxychloroquine 3"/>
  <result pre="treat COVID-19 patients National Institute of Health and Medical Research," exact="France" post="NCT04315948 10 Hydroxychloroquine, Oseltamivir, Azithromycin 3 Oral route To"/>
  <result pre="Azithromycin 3 Oral route To treat COVID-19 patients Shehnoor Azhar," exact="Pakistan" post="NCT04338698 11 Hydroxychloroquine and Nitazoxanide 2, 3 Oral route"/>
  <result pre="Oral route To treat COVID-19 patients Intermountain Health Care, Inc.," exact="United States," post="Intermountain Medical Center, United States NCT04329832, NCT04334382 13 1."/>
  <result pre="patients Intermountain Health Care, Inc., United States, Intermountain Medical Center," exact="United States" post="NCT04329832, NCT04334382 13 1. Lopinavir/ritonavir,2. Ribavirin and3. Interferon beta-1b"/>
  <result pre="3 S.C injection To treat COVID-19 patients The University of" exact="Hong Kong," post="Hong Kong NCT04276688 14 Clevudine 2 Oral route Antiviral,"/>
  <result pre="injection To treat COVID-19 patients The University of Hong Kong," exact="Hong Kong" post="NCT04276688 14 Clevudine 2 Oral route Antiviral, to evaluate"/>
  <result pre="to treat patients with COVID-19 pneumonia Jieming QU, Ruijin Hospital," exact="China" post="NCT04260594 16 Isotretinoin 3 Oral route Retinoid, to evaluate"/>
  <result pre="to evaluate the safety and efficacy in COVID-19 Tanta University," exact="Egypt" post="NCT04361422 17 Ivermectin and Nitazoxanide 2, 3 Oral route"/>
  <result pre="safety and efficacy of the combination in COVID-19 Tanta University," exact="Egypt" post="NCT04360356 18 Recombinant human Interferon Î±1Î² 1 Nebulization To"/>
  <result pre="Interferon Î±1Î² 1 Nebulization To treat COVID-19 patients Tongji Hospital," exact="China" post="NCT04293887 19 1.Bromhexine hydrochloride, 2.Arbidol hydrochloride and 3. Recombinant"/>
  <result pre="with COVID-19 pneumonia Second Affiliated Hospital of Wenzhou Medical University," exact="China" post="NCT04273763 20 Deferoxamine 1 &amp;amp; 2 Intravenous infusion Iron"/>
  <result pre="the Severity of COVID-19 Manifestations Kermanshah University of Medical Sciences," exact="Iran" post="NCT04333550 21 Dexamethasone 4 I.V Steroid, to treat patients"/>
  <result pre="patients with ARDS caused by COVID-19 Dr. Negrin University Hospital," exact="Spain" post="NCT04325061 22 Piclidenoson 2 Oral route A3 adenosine receptor"/>
  <result pre="A3 adenosine receptor agonist, to treat COVID-19 patients Can-Fite BioPharma," exact="Israel" post="NCT04333472 23 Favipiravir 3 Oral route Antiviral, to evaluate"/>
  <result pre="to evaluate safety and efficacy in COVID-19 patients Giuliano Rizzardini," exact="Italy" post="NCT04336904 24 Huaier Granule 2 &amp;amp; 3 Oral route"/>
  <result pre="&amp;amp; 3 Oral route Adjuvant treatment of COVID-19 Tongji Hospital," exact="China" post="NCT04291053 25 Tranexamic acid 2 Oral route Antifibrinolytics, to"/>
  <result pre="its effect on COVID-19 The University of Alabama at Birmingham," exact="United States" post="NCT04338126 26 BLD-2660 2 Oral route Antiviral small molecule,"/>
  <result pre="Oral route Antiviral small molecule, to treat COVID-19 Blade Therapeutics," exact="United States" post="NCT04334460 27 Sildenafil citrate 3 Oral route Phosphodiesterase inhibitor,"/>
  <result pre="Oral route Phosphodiesterase inhibitor, to treat COVID-19 patients Tongji Hospital," exact="China" post="NCT04304313 28 Losartan 1 Oral route Angiotensin receptor blocker,"/>
  <result pre="respiratory failure due to COVID-19 University of Kansas Medical Center," exact="United States" post="NCT04335123 29 Telmisartan 2 Oral route Angiotensin receptor blocker,"/>
  <result pre="evaluate the efficacy in COVID-19 patients Laboratorio Elea Phoenix S.A.," exact="Argentina" post="NCT04355936 30 Atorvastatin 2 Oral route Statin, to assess"/>
  <result pre="efficacy of drug to prevent cytokine storm Johns Hopkins University," exact="United States" post="NCT04365257 32 Chlorpromazine 3 Oral route Antipsychotics, to repurpose"/>
  <result pre="repurpose the drug for COVID-19 treatment Centre Hospitalier St Anne," exact="France" post="NCT04366739 33 Lenalidomide 4 Oral route Antiangiogenic agent, to"/>
  <result pre="to treat mild to moderate COVID-19 patients Getafe University Hospital," exact="Spain" post="NCT04361643 34 FT516 - induced pluripotent stem cell 1"/>
  <result pre="of cells in patients with COVID-19 Pneumonia Cell Therapy Network," exact="Spain" post="NCT04361942 36 Human Mesenchymal Stem Cells 1 &amp;amp; 2"/>
  <result pre="factor and to treat patients with COVID-19 pneumonia Puren Hospital," exact="China" post="NCT04339660 37 Anti-SARS-CoV-2 convalescent plasma 2 I.V infusion To"/>
  <result pre="safety and efficacy Medical College of Wisconsin, Hackensack Meridian Health," exact="United States," post="Joakim Dillner, Sweden NCT04354831, NCT04343755, NCT04390178, NCT04384497 38 Anti-SARS-CoV-2"/>
  <result pre="College of Wisconsin, Hackensack Meridian Health, United States, Joakim Dillner," exact="Sweden" post="NCT04354831, NCT04343755, NCT04390178, NCT04384497 38 Anti-SARS-CoV-2 convalescent plasma 3"/>
  <result pre="Service, France,National Institute of Medical Sciences and Nutrition Salvador Zubiran," exact="United Mexican States" post="NCT04372979, NCT04388410 39 Hyperimmune plasma with standard therapy 2"/>
  <result pre="evaluate safety and efficacy in COVID-19 patients University of Catanzaro," exact="Italy" post="NCT04385043 40 bac-TRL-Spike 1 Oral route To prevent COVID-19"/>
  <result pre="Oral route To prevent COVID-19 in Healthy adults Symvivo Corporation," exact="Canada" post="NCT04334980 41 IFX-1 with Best supportive care 2 &amp;amp;"/>
  <result pre="&amp;amp; 3 I.V C5a antibody, to treat pneumonia. InflaRx GmbH," exact="Netherlands" post="NCT04333420 42 Acalabrutinib with Best supportive care 2 Oral"/>
  <result pre="tyrosine kinase inhibitor, To evaluate safety, efficacy and pharmacokinetics AstraZeneca," exact="United States" post="NCT04380688, NCT04346199 43 Baricitinib 2 &amp;amp; 3 I.V Janus"/>
  <result pre="I.V Janus Kinase inhibitor, to treat COVID-19 University of Colorado," exact="United States" post="NCT04340232 44 Tocilizumab 2 I.V injection Immunosuppressive, to treat"/>
  <result pre="COVID-19 pneumonia National Cancer Institute, Naples, University Hospital Inselspital, Berne," exact="Switzerland" post="NCT04317092, NCT04335071 45 Canakinumab 3 I.V infusion Anti-human-IL-1Î² monoclonal"/>
  <result pre="efficacy in COVID-19 patients with cytokine release syndrome Novartis Pharmaceuticals," exact="United States" post="NCT04362813 46 Ruxolitinib 2 â€&quot; Kinase inhibitor, to treat"/>
  <result pre="inflammation in patients with stage II/III COVID-19 Dr. Andreas Hochhaus," exact="Germany" post="NCT04338958 47 Ruxolitinib 3 Oral route To evaluate safety"/>
  <result pre="and efficacy in COVID-19 patients with Cytokine storm Novartis Pharmaceuticals," exact="United Kingdom" post="NCT04362137 48 BCG vaccine 3 Intracutaneous injection To reduce"/>
  <result pre="Absenteeism in COVID-19 UMC Utrecht, Netherlands, Murdoch Children Research Institute," exact="Australia" post="NCT04328441, NCT04327206 49 Artificial Antigen Presenting Cell (aAPC) Vaccine"/>
  <result pre="1 S.C injection To treat COVID-19 Shenzhen Geno-Immune Medical Institute," exact="China" post="NCT04299724 50 ChAdOx1 nCoV-19 Vaccine 1 &amp;amp; 2 I.M"/>
  <result pre="1 &amp;amp; 2 I.M To treat COVID-19 University of Oxford," exact="United Kingdom" post="NCT04324606 8 Recent advancement and future perspective Considerable progress"/>
  <result pre="cause of severe acute respiratory syndrome (SARS) in Guangdong, Peopleâ€™s" exact="Republic of" post="China, in February, 2003Lancet36220031353135810.1016/S0140-6736(03)14630-214585636 7HuangC.WangY.LiX.RenL.ZhaoJ.HuY.ZhangL.FanG.XuJ.GuX.ChengZ.YuT.XiaJ.WeiY.WuW.XieX.YinW.LiH.LiuM.XiaoY.GaoH.GuoL.XieJ.WangG.JiangR.GaoZ.JinQ.WangJ.CaoB.Clinical features of patients infected"/>
  <result pre="20Severe outcomes among patients with coronavirus disease 2019 (COVID-19) â€&quot;" exact="United States," post="February 12â€&quot;March 16, 2020 | MMWR, (n.d.). https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm (accessed"/>
  <result pre="insights into the structure of the coronavirionProc. Natl. Acad. Sci." exact="U. S." post="A.106200958258710.1073/pnas.080527010619124777 26TsengY.-T.ChangC.-H.WangS.-M.HuangK.-J.WangC.-T.Identifying SARS-CoV membrane protein amino acid residues linked"/>
  <result pre="integrates processive RNA polymerase and exonuclease activitiesProc. Natl. Acad. Sci." exact="U. S." post="A.1112014E3900E390910.1073/pnas.132370511125197083 51HsuJ.T.-A.KuoC.-J.HsiehH.-P.WangY.-C.HuangK.-K.LinC.P.-C.HuangP.-F.ChenX.LiangP.-H.Evaluation of metal-conjugated compounds as inhibitors of 3CL"/>
  <result pre="Biol. Sci.1620201724173110.7150/ijbs.4549832226290 56CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, evaluation and treatment coronavirus (COVID-19)StatPearls2020StatPearls PublishingTreasure" exact="Island" post="(FL)http://www.ncbi.nlm.nih.gov/books/NBK554776/ 57LiG.ClercqE.D.Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nat."/>
  <result pre="fusion inhibition by the antiviral drug ArbidolProc. Natl. Acad. Sci." exact="U. S." post="A.114201720621410.1073/pnas.161702011428003465 100ZengL.-Y.YangJ.LiuS.Investigational hemagglutinin-targeted influenza virus inhibitorsExpert Opin. Investig. Drugs262017637310.1080/13543784.2017.1269170"/>
  <result pre="University Novel Coronavirus Management and Research TeamEvidence-Based Medicine Chapter of" exact="China" post="International Exchange and Promotive Association for Medical and Health"/>
  <result pre="treatment of severe COVID-19 patients with tocilizumabProc. Natl. Acad. Sci." exact="U. S." post="A.1172020109701097510.1073/pnas.200561511732350134 164RuanQ.YangK.WangW.JiangL.SongJ.Clinical predictors of mortality due to COVID-19 based"/>
  <result pre="search and a narrative review with a special reference to" exact="India" post="and other developing countriesDiabetes &amp;amp; Metabolic Syndrome: Clinical Research"/>
  <result pre="Environ.725202013827710.1016/j.scitotenv.2020.13827732278175 Acknowledgement The authors acknowledge European Molecular Biology Organization (EMBO)," exact="Germany" post="for providing EMBO Short-term Fellowship to Dr. Abhjeet Pandey."/>
  <result pre="thankful to i) Manipal Academy of Higher Education (MAHE), Manipal," exact="India" post="(for Postdoctoral Fellowship to Dr Abhijeet Pandey and Dr"/>
  <result pre="Delhi (for Senior Research Fellowship to Divya Gopalan) and All" exact="India" post="Council for Technical Education (AICTE), Government of India, New"/>
  <result pre="to Manipal and Manipal College of Pharmaceutical Sciences, MAHE, Manipal," exact="India" post="for providing necessary facilities."/>
 </snippets>
</snippetsTree>
